Entrada Therapeutics, Inc. (TRDA) Tops Q2 EPS by $1.19

Entrada Therapeutics, Inc. (NASDAQ: TRDA) reported Q2 EPS of $1.55, $1.19 better than the analyst estimate of $0.36. Revenue for the quarter came in at $94.7 million versus the consensus estimate of $51.86 million.

For earnings history and earnings-related data on Entrada Therapeutics, Inc. (TRDA) click here.

You May Also Be Interested In

• Flowers Foods (FLO) Misses Q2 EPS by 3c; Offers Guidance
• Largo restructures $82.2M in debt, extending maturity to 2030
• Etsy upgraded to buy at BofA on durable growth, buyback potential